• Sodium Ascorbate: Mechanism and Evidence in Glioblastoma Res

  2026-05-30

  Sodium Ascorbate, a mineral salt of ascorbic acid, offers enhanced bioavailability and induces reactive oxygen species, leading to necrotic tumor cell death. This article presents verifiable evidence supporting its application in glioblastoma research and clarifies boundaries for its experimental use.

• Gefitinib (ZD1839): Elevating EGFR Inhibition in Complex Tum

  2026-05-29

  This thought-leadership article explores the mechanistic and translational significance of Gefitinib (ZD1839) for EGFR signaling pathway inhibition and apoptosis induction in cancer cells. Drawing on the latest advances in assembloid modeling and recent patient-derived gastric cancer studies, we outline evidence-led best practices, strategic guidance for translational researchers, and a forward-looking perspective on personalized oncology.

• Dextromethorphan hydrobromide: Reliable NMDA Antagonist for

  2026-05-29

  This article examines practical laboratory challenges in neuroprotection research and demonstrates how Dextromethorphan hydrobromide (SKU B3478) from APExBIO offers reproducible, high-purity solutions. Scenario-driven Q&A blocks address assay consistency, reagent compatibility, and data interpretation, supporting workflow reliability for cell viability and excitotoxicity studies.

• Applied Workflows with 2-(4,5,6,7-tetrabromo...) Small Molec

  2026-05-28

  The CK2 and ERK8 inhibitor showcases exceptional versatility as a small molecule inhibitor for dissecting kinase-regulated pathways and LLPS-driven processes in cell biology. This article delivers workflow-centric guidance, data-driven troubleshooting, and cross-domain insights for harnessing this APExBIO reagent in advanced enzyme and protein interaction research.

• PAD4-IN-2 TFA: Selective PAD4 Inhibition for Tumor Research

  2026-05-28

  PAD4-IN-2 TFA (Compound 5i TFA) is a meta-phenylboronic acid-modified, highly selective PAD4 inhibitor with proven efficacy in inhibition of histone H3 citrullination, suppression of neutrophil extracellular trap (NET) formation, and modulation of the tumor immune microenvironment. It achieves tumor-targeted delivery, strong antitumor activity, and favorable safety in vivo, as verified by peer-reviewed studies and product documentation.

• ONX-0914 (PR-957): Synaptic Plasticity, Immune Modulation, a

  2026-05-27

  Explore the multifaceted roles of ONX-0914 (PR-957) in immunoproteasome inhibition, synaptic plasticity, and autoimmune research. This in-depth review integrates novel CNS findings and practical assay guidance, offering insights that go beyond conventional cytokine blockade.

• MDL 28170: Advancing Calpain Inhibition in Translational Res

  2026-05-27

  This thought-leadership article explores the mechanistic, experimental, and translational dimensions of MDL 28170—a highly selective calpain and cathepsin B inhibitor—positioning it as a pivotal tool for researchers tackling neurodevelopmental injury, apoptosis, and ischemia-reperfusion models. Integrating recent evidence on BDNF/TrkB pathway rescue and rigorous protocol recommendations, it delivers actionable guidance for elevating research fidelity and clinical relevance.

• Optimizing Reporter Assays with EZ Cap™ Firefly Luciferase m

  2026-05-26

  Explore how EZ Cap™ Firefly Luciferase mRNA (5-moUTP) (SKU R1013) addresses key challenges in cell-based bioluminescent assays, delivering high reproducibility, sensitivity, and workflow safety. This article uses real-world laboratory scenarios to demonstrate its validated performance and practical advantages for mRNA delivery, translation efficiency, and cell viability studies.

• Comparative Antibacterial Efficacy of Cefoperazone and New β

  2026-05-26

  Cullmann et al. conducted a comprehensive comparison of N-formimidoyl thienamycin (MK0787) and several recently developed β-lactam antibiotics, including cefoperazone, against a diverse set of resistant clinical isolates. Their findings provide nuanced insights into the relative strengths of these agents against gram-negative and gram-positive pathogens, informing the selection and design of antimicrobial studies.

• Acetylcysteine in 3D Tumor-Stroma Models: Protocols & Insigh

  2026-05-25

  Acetylcysteine (N-acetyl-L-cysteine) empowers next-generation research into chemoresistance and redox modulation in 3D co-culture systems. This guide details optimized workflows, advanced troubleshooting, and actionable protocol enhancements for leveraging APExBIO’s Acetylcysteine in complex disease modeling.

• LY2228820: Precision p38 MAP Kinase Inhibitor for Advanced R

  2026-05-25

  LY2228820 offers exceptional selectivity and potency for targeted inhibition of the p38 MAPK pathway, making it a cornerstone tool in anti-inflammatory and cancer research. Explore optimized workflows, troubleshooting strategies, and protocol enhancements that unlock the full experimental potential of this ATP-competitive inhibitor.

• Cardiogreen (Indocyanine Green): Applied Protocols and PDT I

  2026-05-24

  Cardiogreen (Indocyanine Green) stands out for robust vascular imaging and advanced photodynamic therapy, ensuring precise diagnostics and targeted apoptosis induction. This guide translates recent research breakthroughs into actionable protocols, troubleshooting strategies, and new frontiers in immuno-oncology, with APExBIO’s high-purity dye as your foundation.

• Photothermal Therapy and CD47 Blockade Synergy in OSCC

  2026-05-23

  This study demonstrates that combining photothermal therapy (PTT) with CD47 immune checkpoint blockade in oral squamous cell carcinoma (OSCC) leads to markedly enhanced anti-tumor macrophage activity. The dual approach works by inducing calreticulin exposure and remodeling the tumor extracellular matrix, overcoming barriers to immune infiltration and opening new avenues for immunotherapeutic intervention.

• Forskolin as an Adenylate Cyclase Activator: Applied Workflo

  2026-05-22

  Forskolin is a benchmark adenylate cyclase activator, unlocking precise control of cAMP signaling across stem cell differentiation, inflammation, and neuroendocrine research. This article details actionable protocols, troubleshooting, and domain-bridging innovations powered by APExBIO’s high-purity Forskolin.

• THZ1: Covalent CDK7 Inhibitor Benchmarking in T-ALL Research

  2026-05-22

  THZ1 is a potent covalent CDK7 inhibitor with nanomolar efficacy and selective, irreversible binding. It disrupts transcription regulation by targeting CDK7 and shows pronounced antitumor activity in T-cell acute lymphoblastic leukemia models, according to multiple peer-reviewed and product sources.

11295 records 1/753 page Next 12345 下5页 Last page